Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nymox Pharmaceutical Corp (NASDAQ:NYMX)

3.19
Delayed Data
As of 11:49am ET
 -0.03 / -0.93%
Today’s Change
1.62
Today|||52-Week Range
5.79
-2.74%
Year-to-Date
The Pockets of Speculative Action Have Dried Up
Nov 29 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close3.22
Today’s open3.25
Day’s range3.15 - 3.25
Volume63,620
Average volume (3 months)1,070,317
Market cap$154.2M
Dividend yield--
Data as of 11:49am ET, 12/05/2016

Growth & Valuation

Earnings growth (last year)-269.23%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)-6.38%
P/E ratioNM
Price/Sales44.43
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AKAOAchaogen Inc-0.12-2.14%
ALBOAlbireo Pharma Inc-0.79-3.12%
VTLVital Therapies Inc0.000.00%
VVUSVIVUS Inc-0.00-0.36%
Data as of 11:54am ET, 12/05/2016

Financials

Last reporting dateMarch 11, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$2.8M
Annual profit (last year)-$17.9M
Net profit margin-647.67%

Profile

Sector
Health Technology
Industry
Medical Specialties
Chairman, President &
Chief Executive Officer
Paul Averback
Chief Financial Officer &
Secretary
Erik Danielsen
Corporate headquarters
Saint-Laurent, Quă©bec

Forecasts


Search for Jobs